Absence of Interference on in vitro Clinical Diagnostic Assays Often Performed on Hospitalized Patients by Relmapirazin, a Fluorescent Tracer Agent for Point-of-Care Assessment of Glomerular Filtration Rate.

Authors

Richard B Dorshow, Nancy Morrison, Margot Borgel

Published in

International journal of toxicology. Pages 10915818261477667. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

The FDA has recently approved a medical device which determines a glomerular filtration rate assessment at the point-of-care by transdermal detection of the fluorescent tracer agent relmapirazin. Previous in vitro and in vivo studies on this agent yielded negligible safety/toxicology concern resulting in advancement to phase I, II, and III human clinical studies. Now that clinical use is occurring, herein we investigated possible interference this agent may induce with typical clinical diagnostic assays given to incoming and hospitalized patients. The testing methodology followed the CLSI EP07-A3 Interference Testing in Clinical Chemistry guideline for determination of interference. No interference from relmapirazin was detected in the suite of metabolic and cardiac assays evaluated.

PMID:
42607154
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.